북미 임상 시장에서의 마이코플라스마 테스트 – 2030년까지의 산업 동향 및 예측

북미 임상 시장 분석 및 규모에서의 마이코플라스마 테스트

COPD가 미국에서 장애와 사망의 주요 원인이라는 것이 입증되었습니다. 1,250만 명 이상이 COPD 진단을 받았지만 수백만 명의 사람들이 알지도 못한 채 이 질병을 앓고 있습니다. 폐 질환, 호흡기 질환 및 결핵으로 인한 사망자 수가 증가했으며, 이 수치는 향후 몇 년 동안 더욱 증가할 것으로 예상되어 시장 성장이 증가할 것입니다.  

Data Bridge Market Research는 2023-2030년 예측 기간 동안 임상 시장에서 마이코플라스마 검사의 성장률을 분석합니다. 임상 시장에서 마이코플라스마 검사의 예상 CAGR은 언급된 예측 기간 동안 약 7.30%인 경향이 있습니다. 시장은 2022년에 1억 3,690만 달러로 평가되었으며, 2030년까지 2억 4,055만 달러까지 성장할 것입니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자 및 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

북미 임상 시장 범위 및 세분화에서의 마이코플라스마 테스트

시장 정의

Mycoplasma testing is widely used to identify an active or recent mycoplasma infection, which is a kind of bacterial infection. Testing may be done in a number of ways depending on which one is suspected, as there are different types of mycoplasma infections such as Mycoplasma is M. pneumoniae, which causes upper respiratory infections and can be further tested with a blood sample.  

North America Mycoplasma Testing in Clinical Dynamics

Drivers

• Growing Adoption of PCR

PCR has been growing adoption in the last few years for quick detection and fast results. For instance, the CFX96 Touch Real-Time PCR Detection System from Bio-Rad Laboratories is based on PCR. This system is a versatile and accurate PCR detection system with six channels that consist of cutting-edge optical technique and exact temperature control. Consequently, both multiplex and singleplex reactions can be detected using this trustworthy and sensitive method. Therefore, this factor increases the growth of the market.

• Launch of Newer Technologies

The growing adoption of new technologies for drug research and development and advancements in cell culture technology boosts the growing need for mycoplasma tests. For instance, bioMérieux SA launched a molecular biology test termed BIOFIRE MYCOPLASMA test in July 2020, to detect mycoplasma in biotherapeutics. This is an innovative and easy to use test that can increase the detection of mycoplasma in biopharmaceutical products. This factor improves the market growth.

Opportunities

• Higher Demand of Kits and Reagents

The market is seem to rise due to the increased demand for these products in mycoplasma detection, and their high cost. Numerous market players have developed mycoplasma detection kits particularly to the needs of researchers and biologic manufacturers, which is boosting segment growth. Instruments are expected to experience major growth during the forecast period because of the increasing availability of automated equipment for the detection of mycoplasma. Thus, this factor created much opportunity for the market growth.

• Increase Incidence of Respiratory Tract Infections

The incidence of respiratory tract infections reported by numerous studies ranges from 20 to 30% in the U.S. In adults, upper respiratory tract infection were caused mostly by S. pneumoniae (21.62%) and LRTIs by human rhinovirus (26.47%). In the elderly group, URTIs were caused mostly by influenza A virus (33.33%), human rhinovirus (33.33%), and LRTIs by S. pneumoniae (50%) and human adenovirus (50%). Thus, this factor increases the growth of the market.

 Restraints/Challenges

• Inadequate Reimbursement Policies

Even though several testing products were launched, but not all the products have been launched at a cheap price. An inadequate reimbursement scenario is estimated to restrict the use of mycoplasma testing and reduce the growth of the market during the forecast period 2023-2030. Thus, this hampers the market growth.

This mycoplasma testing in clinical market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the mycoplasma testing in clinical market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth. 

North AmericaMycoplasma Testing in Clinical Market Scope

The mycoplasma testing in clinical market is segmented on the basis of products, technique, disease area and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Products

• Kits and Reagents
• Instruments
• Services

Technique

• Microbial Culture Techniques/Direct Assay
• Polymerase Chain Reaction
• ELISA
• DNA Staining/Indirect Assay
• Enzymatic Methods

Disease Area

• Respiratory
• Urogenital
• Gastrointestinal
• Musculoskeletal
• Cardiovascular
• Others

End-User

• Diagnostic Laboratories
• Hospitals

Mycoplasma Testing in Clinical Market Regional Analysis/Insights

The mycoplasma testing in clinical market is analyzed and market size insights and trends are provided by products, technique, disease area and end user as referenced above.

The major countries covered in the mycoplasma testing in clinical market report are U.S., Canada and Mexico.

The U.S. is leading the market due to increased healthcare funding. In North America region, kits & reagents segment is anticipated to increase the market growth in the forecast period of 2020 to 2027 due to growing mycoplasma testing in clinical field and research development for identification of mycoplasma cell culture contamination.  

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed base and New Technology Penetration

임상 시장에서의 마이코플라스마 검사는 또한 모든 국가에 대한 자세한 시장 분석을 제공합니다. 자본 장비에 대한 의료 지출 증가, 태반줄기세포(PSCS) 시장을 위한 다양한 종류의 제품 설치 기반, 생명선 곡선을 사용한 기술의 영향, 의료 규제 시나리오의 변화 및 태반줄기세포(PSCS) 시장에 미치는 영향. 이 데이터는 2011-2021년의 과거 기간에 대해 제공됩니다.

경쟁 환경 및 북미 임상 시장 점유율 분석에서의 마이코플라스마 테스트

임상 시장 경쟁 환경에서의 마이코플라스마 테스트는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 중동 및 아프리카 지역, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 제공된 위의 데이터 포인트는 임상 시장에서의 마이코플라스마 테스트와 관련된 회사의 초점에만 관련이 있습니다.

임상 시장에서 마이코플라스마 테스트에 참여하는 주요 업체는 다음과 같습니다.

• AB ANALITICA srl(이탈리아)
• 비오메리유(프랑스)
• ELITechGroup(프랑스)
• Liofilchem ​​Srl(이탈리아)
• Agilent Technologies, Inc. (미국)
• PromoCell GmbH(독일)
• F. 호프만-라 로슈 유한회사(스위스)
• 오상헬스케어(한국)
• Sacace Biotechnologies Srl(이탈리아)
• 론자(스위스)
• 머크 KGaA(독일)
• Seegene Inc. (한국)
• Clongen Laboratories, LLC(미국)
• Bio-Rad Laboratories, Inc. (미국)
• 찰스 리버 연구소(미국)
• Bionique Testing Laboratories LLC(미국)
• ZEAKON 진단(인도) 

SKU-44730